Mundipharma EDO GmbH
🇨ðŸ‡Switzerland
Tinostamustine Conditioning and Autologous Stem Cell
Phase 1
Terminated
- Conditions
- Multiple Myeloma ProgressionMultiple Myeloma With Failed RemissionMultiple Myeloma in Relapse
- Interventions
- Procedure: Autologous Stem Cell Transplant (ASCT)
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Mundipharma-EDO GmbH
- Target Recruit Count
- 6
- Registration Number
- NCT03687125
- Locations
- 🇨ðŸ‡
Universitatsspital Bern, Bern, Switzerland
🇺🇸Memorial Sloan Kettering Cancer Centre, New York, New York, United States
🇺🇸Carolinas Healthcare System, Charlotte, North Carolina, United States
© Copyright 2025. All Rights Reserved by MedPath